In the absence of a submission from the holder of the marketing authorisation, bevacizumab (Avastin®) cannot be endorsed for use within NHS Wales for use in combination with carboplatin and paclitaxel for the treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.